18456339. DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF simplified abstract (Fred Hutchinson Cancer Center)
Contents
- 1 DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF
Organization Name
Inventor(s)
Irwin D. Bernstein of Seattle WA (US)
Suzanne Furuyama of Mountlake Terrace WA (US)
Kristen Johnson of Seattle WA (US)
DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF - A simplified explanation of the abstract
This abstract first appeared for US patent application 18456339 titled 'DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF
Simplified Explanation
The abstract describes the disclosure of Delta-like non-canonical Notch ligand 1 (DLK1) inhibitors for the treatment of various cancers, including myelodysplastic syndrome (MDS) and cancers of the liver, breast, brain, pancreas, colon, lung, kidney, ovary, testes, and/or adrenal gland.
- DLK1 inhibitors are disclosed for the treatment of cancers such as MDS and various other types.
- These inhibitors can be used in the treatment of liver, breast, brain, pancreas, colon, lung, kidney, ovary, testes, and/or adrenal gland cancers.
Potential Applications
The potential applications of DLK1 inhibitors include:
- Treatment of myelodysplastic syndrome (MDS)
- Treatment of various cancers, including liver, breast, brain, pancreas, colon, lung, kidney, ovary, testes, and adrenal gland cancers
Problems Solved
The DLK1 inhibitors address the following problems:
- Lack of effective treatment options for MDS and certain types of cancers
- Need for targeted therapies for specific cancer types
Benefits
The benefits of DLK1 inhibitors include:
- Potentially improved treatment outcomes for patients with MDS and various cancers
- Targeted therapy that may reduce side effects associated with traditional treatments
Potential Commercial Applications
The potential commercial applications of DLK1 inhibitors can include:
- Pharmaceutical companies developing and marketing these inhibitors for cancer treatment
- Research institutions utilizing DLK1 inhibitors for further studies on cancer therapy
Possible Prior Art
One possible prior art in this field could be the use of other Notch pathway inhibitors for cancer treatment, such as gamma-secretase inhibitors. These inhibitors have been studied for their potential in targeting Notch signaling in cancer cells.
Unanswered Questions
How do DLK1 inhibitors compare to other targeted therapies for cancer treatment?
DLK1 inhibitors may offer a unique mechanism of action compared to other targeted therapies, but further studies are needed to determine their efficacy and safety profile in comparison to existing treatments.
What are the potential side effects of DLK1 inhibitors in cancer patients?
The potential side effects of DLK1 inhibitors need to be thoroughly evaluated in clinical trials to ensure their safety and tolerability in cancer patients.
Original Abstract Submitted
Delta-like non-canonical Notch ligand 1 (DLK1) inhibitors are disclosed. The DLK1 inhibitors can be used to treat cancers such as myelodysplastic syndrome (MDS), and cancers of the liver, breast, brain, pancreas, colon, lung, kidney, ovary, testes, and/or adrenal gland, among other uses described herein.
